Provider Information

Title	Summary	Presenter/Author	Subject Area	Type	hf:doc_tags	hf:doc_author
2022 CDC Clinical Practice Guideline at a Glance \| Overdose Prevention	What to know The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain (2022 …		Opioid Use Disorders, Provider Information
Proposed Position on Supervised Withdrawal Management (December 2023)	…		Practices, Provider Information	document	document
Best and Promising Practices \| Adding Fentanyl Testing to Hospital Toxicology Assays	…		Educational Resources, Fentanyl, Provider Information	video, webinar	video webinar
Cytochrome P Four Who? Demystifying Pharmacokinetic Drug Interactions	Stephanie Nichols PharmD, BCPP, BCPS, MPH presents a training session on Pharmacokinetic Drug Interaction from …		Educational Resources, Provider Information, Stimulant Use	video, webinar	video webinar
Cannabis Use and Psychosis in Adolescents	Presented by Amy Mayhew, MD, MPH in partnership with ME SUD Learning Community on …		Adolescence / Youth, Cannabis, Educational Resources, Project ECHO, Provider Information	video, webinar	video webinar
What is Xylazine?	What is Xylazine? − A non-opioid agent that the FDA originally approved in 1972 as a sedative and analgesic for use in veterinary medicine (not FDA approved for use in humans) − Acts as a central alpha-2-adrenergic receptor agonist in the brainstem (like clonidine) o Rapid decrease in the release of norepinephrine and dopamine in the central nervous system (CNS) o May also bind to other CNS receptors		Educational Resources, Patient & Provider Information, Provider Information
Proposed Position on the Use of Buprenorphine-Naloxone in Pregnancy (March 2020)	…		Educational Resources, Provider Information
Pain Management and Opioids CME & Disclosures	NEJM Knowledge+ Pain Management and Opioids consist of 62 in-depth, case-based scenarios developed by practicing …		Educational Resources, Provider Information
Diagnosis and treatment of ADHD in adults with Substance Use Disorder: Applying Evidence to a Common Clinical Quandry	Diagnosis and Treatment of ADHD in Adults with Substance Use Disorder: Applying Evidence to a Common Clinical Quandary \| November 10, 2022 \| Andrea Truncali, Lauren Moran, and Margaret Chaplin Diagnosis and treatment of adult ADHD is on the rise. Patients with substance use disorder are thought to be disproportionately affected by ADHD but how safe is, and what impact does the pharmacologic treatment have?	Andrea Truncali MD MPH, Lauren Moran, Margaret Chaplin	Educational Resources, Provider Information, Stimulant Use	video, webinar	video webinar	andrea-truncali-md-mph lauren-moran margaret-chaplin
SAMHSA Buprenorphine Quick Start Guide	Facts About Buprenorphine FDA approved for Opioid Use Disorder treatment in an officebased setting. …		Provider Information